5-Hydroxytryptophan (5-HTP) is a naturally occurring amino acid and chemical precursor to serotonin. It is commonly used to support mood, sleep quality, and appetite regulation by increasing serotonin levels in the brain.

Overview

5-Hydroxytryptophan (5-HTP) is an intermediate metabolite in the biosynthesis of serotonin from the essential amino acid L-tryptophan. It is produced endogenously by the enzyme tryptophan hydroxylase and is also found naturally in the seeds of the African plant Griffonia simplicifolia. Once ingested, 5-HTP readily crosses the blood-brain barrier and is converted to serotonin (5-hydroxytryptamine) by aromatic L-amino acid decarboxylase, making it a more efficient serotonin precursor than tryptophan itself.

Clinical research has investigated 5-HTP for a range of conditions associated with low serotonin activity, including depression, insomnia, fibromyalgia, migraine headaches, and obesity. Several small trials have reported improvements in depressive symptoms comparable to certain SSRIs, though large-scale, high-quality studies remain limited. Its effects on appetite suppression have been attributed to enhanced serotonergic signaling in hypothalamic satiety centers.

5-HTP is generally well tolerated at typical oral doses of 50-300 mg per day, though gastrointestinal side effects such as nausea and diarrhea can occur. Co-administration with serotonergic medications (SSRIs, MAOIs, triptans) carries a theoretical risk of serotonin syndrome and should be avoided without medical supervision. Long-term supplementation is sometimes paired with a peripheral decarboxylase inhibitor like carbidopa to prevent excessive peripheral serotonin production.

Mechanism of Action

Serotonin Biosynthesis Pathway

5-Hydroxytryptophan (5-HTP) is the immediate biosynthetic precursor to serotonin (5-hydroxytryptamine, 5-HT). Unlike tryptophan, 5-HTP freely crosses the blood-brain barrier without competing for transport with other large neutral amino acids (PMID: 9727088).

Enzymatic Conversion

Once absorbed, 5-HTP is decarboxylated by aromatic L-amino acid decarboxylase (AADC, EC 4.1.1.28) to produce serotonin. This enzyme is present in both CNS serotonergic neurons and peripheral tissues (gut enterochromaffin cells, kidneys). The conversion is rapid and does not require biopterin cofactors, unlike the rate-limiting tryptophan hydroxylase step it bypasses (PMID: 10696570).

Downstream Serotonergic Signaling

Elevated serotonin activates the 5-HT receptor family (5-HT1A, 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, etc.), modulating mood, appetite, sleep-wake cycles, and nociception. In the CNS, increased 5-HT1A autoreceptor activation initially dampens firing rates in dorsal raphe neurons, with desensitization over days leading to sustained serotonergic enhancement.

Melatonin Pathway

Serotonin also serves as a substrate for melatonin synthesis in the pineal gland. Serotonin is acetylated by arylalkylamine N-acetyltransferase (AANAT) to form N-acetylserotonin, then methylated by hydroxyindole O-methyltransferase (HIOMT) to produce melatonin, linking 5-HTP supplementation to circadian rhythm regulation (PMID: 15070165).

Peripheral Effects

Approximately 95% of serotonin resides in the gut, where 5-HTP-derived serotonin modulates GI motility via enteric nervous system 5-HT3 and 5-HT4 receptors. Peripheral conversion can be mitigated by co-administration of carbidopa, a peripheral AADC inhibitor.

Reconstitution Calculator

Research

Safety Profile

Safety Profile: 5-HTP (5-Hydroxytryptophan)

Common Side Effects

• GI effects (most common): Nausea, vomiting, diarrhea, heartburn, stomach pain — dose-dependent, often significant above 300 mg/day
• CNS effects: Drowsiness, dizziness, headache, vivid dreams
• Other: Decreased appetite (may be therapeutic for weight management), muscle tenderness

Serious Adverse Effects

• Serotonin syndrome: Life-threatening risk when combined with serotonergic drugs — symptoms include agitation, hyperthermia, tachycardia, clonus, diaphoresis
• Eosinophilia-myalgia syndrome (EMS): Historical concern from contaminated L-tryptophan (1989); modern 5-HTP is derived from Griffonia simplicifolia seeds, but contamination risk with "peak X" has been reported in some preparations
• Cardiac valvulopathy: Theoretical concern — 5-HTP raises peripheral serotonin, which is implicated in cardiac valve fibrosis (similar mechanism to fenfluramine); long-term risk not fully characterized

Contraindications

• Concurrent use with MAOIs (absolute contraindication — severe serotonin syndrome risk)
• Concurrent use with SSRIs/SNRIs without medical supervision
• Carcinoid tumors (serotonin-producing tumors)
• Down syndrome (increased sensitivity to serotonergic agents reported)
• Planned surgery (discontinue 2 weeks prior — serotonin affects platelet aggregation)

Drug Interactions

• SSRIs/SNRIs (fluoxetine, sertraline, venlafaxine, duloxetine): HIGH RISK — serotonin syndrome; do not combine without specialist supervision
• MAOIs (phenelzine, tranylcypromine, selegiline): CONTRAINDICATED — severe serotonin syndrome
• Triptans (sumatriptan): Additive serotonergic effects; avoid concurrent use
• Tramadol, meperidine, dextromethorphan: Serotonin syndrome risk
• Carbidopa: Dramatically increases 5-HTP bioavailability (historically used together) but also increases peripheral serotonin and side effects
• St. John's Wort: Additive serotonergic effect; avoid combination

Special Populations

• Pregnancy/Lactation: Contraindicated — serotonin is critical for fetal development; exogenous manipulation may be harmful
• Pediatric: Insufficient safety data; not recommended
• Elderly: Start at low doses (50 mg); increased sensitivity to serotonergic effects and falls risk from drowsiness
• Hepatic/renal impairment: Limited data; 5-HTP is converted peripherally and centrally — use with caution

Monitoring Recommendations

• Monitor for serotonin syndrome symptoms (first 24 hours with new combinations)
• Eosinophil count if unexplained myalgia develops
• Echocardiography consideration with prolonged high-dose use (>6 months at >200 mg/day) given cardiac valvulopathy concern
• Blood pressure and heart rate
• Mood and behavioral monitoring (paradoxical anxiety/agitation possible)

Regulatory Note: 5-HTP is a dietary supplement in the US (not FDA-approved as a drug). It is a prescription medication in some European countries. Quality varies between manufacturers; third-party tested products are preferable.

Pharmacokinetic Profile